

## Interim Report Quarter 2, 2025



July 17, 2025

### Ulrika Kolsrud

President and CEO





#### Highlights Q2 2025 Stability in a challenging world

- Positive organic sales growth
- Strong growth in strategic segments
- Weak economy and uncertain environment lead to limited volume growth
- High pace of product launches
- Stable profit although impacted by low volume growth and higher costs
- Sequentially stronger margins



#### Health & Medical Business highlights

- Growing Medical Solutions for 17 consecutive quarters
- Weaker conditions in specific markets impacted
  Incontinence Care Health care
- Continued underlying strong demand for solutions
  addressing chronic conditions
- Launch of TENA Bariatric Range, 3XL-4XL





#### Consumer Goods Business highlights

- Strong growth in Incontinence Care Retail and Feminine Care
- Baby Care challenged by competitive pressure targeted activities to come back to growth
- Consumer Tissue growth in low/mid tier segments
- Strong launches along good-better-best spectrum



















NEVER JUST A PERIOD, BODYFORM/LIBRESSE

#### Professional Hygiene Business highlights

- Good growth in strategic products
- Challenging market conditions both in North America and Europe, especially in HoReCa
- Selective price management
- Launch of Tork Matic<sup>®</sup> Sensor Dispenser with 6 years battery time







Essity awarded supplier engagement leader by CDP and confirmed constituent of the FTSE4Good Index Series Supplier Engagement Leader

**NCDP** 

2024





This is to certify that

Essity Aktiebolag B

4Good Index Series is designed to identity companies that demo environmental, social and governance practices measured agai

## Fredrik Rystedt

**Executive Vice President and CFO** 





#### Stable volumes and higher sales prices



#### EBITA margin excl. IAC



#### Cash flow generation



**Bessity** 

#### Strong balance sheet



### Ulrika Kolsrud

President and CEO







#### Summary

- Q2 Organic growth and stable profit in a weak economy
  - Lower volume growth than expected
  - Strong growth in strategic segments
  - High pace of product launches
  - Stable profitability although impacted by low volume growth and higher costs

#### Priorities 2025

- Continue to execute on our strategy
- Accelerate profitable volume growth
- Reduce cost level and increase efficiency

This presentation may contain forward-looking statements. Such statements are based on our current expectations and are subject to certain risks and uncertainties that could negatively affect our business. Please read our most recent annual report for a better understanding of these risks and uncertainties.



Every day our brands care for the hygiene and health of a billion people across 150 countries





# Forcervoc y and yey body



